☀️☀️@VIPStudy1 is fully open at all sites ➡️ https://t.co/N9vVnZlIX3
📢IBD and no IBD folk ➡️ covid vaccination study.
✅Have you had 2 doses of 💉 < 92 days ago?
✅IBD patients 👉 on only:
Vedo
IFX
Aza/MP
Tofu
Uste
+ IFX + Aza/MP
Check out 👉https://t.co/2H3ggysoIA
What's the relationship between mood and physical health, when it comes to Crohn's and Colitis?
The @mindbody_ibd is investigating that very question, and they're offering £15 worth of vouchers to those taking part.
Find out more 👇
https://t.co/IVZLmf7MHL
👀More data from @VIPStudy1
Main message for #IBDpatients -
✔️ get NEW boosters = protection against Omicron variants.
New boosters especially ☑️☑️ for those on anti -TNF and tofacitinib drugs.
#COVID19Ab#IBD@AGA_Gastro@NickPowellLab
https://t.co/IXhWUmaTUt
Beautifully presented James Alexander. There is a lot of research fatigue around covid. REMEMBER covid vaccines work in IBD. Even when our drugs impair that response, further boosters “rescue’ the deficit. GET YOUR BOOSTER this Autumn.
The last of the late breakers is presented by James Alexander @ImperialMDR, with data from @VIPStudy1 looking at COVID-19 vaccine-induced antibody & T-cell responses in immunosuppressed patients with inflammatory bowel disease after the 3rd vaccine dose #UEGWeek#gitwitter#IBD
The latest @LancetGastroHep podcast is now online—I had the pleasure of speaking to James Alexander of @ImperialMDR about the latest @VIPStudy1 data on #COVID19 vaccine responses in patients with #IBD
Listen: https://t.co/XDTBhuxe0u
Paper: https://t.co/8llo7sJDbZ
Latest findings from the @VIPStudy1: a third dose of SARS-CoV-2 vaccine resulted in antibody levels significantly higher than after the second dose in patients with #IBD, irrespective of type of immunosuppressive therapy (1/6)
https://t.co/D0ERnvyfhN #gitwitter#covid19
Withdrawal of @BritSocGastro IBD risk grid for COVID severity @Gut_BMJ
• reassuring for patients, with
• vaccines, boosters and antivirals
"We predict that the disruption from the pandemic for individuals with IBD will largely be no different to the general population."
Tomorrow marks the start of #ECCO2022 and a busy few days for @NickPowellLab We have two talks in the main scientific programme: James Alexander with the latest @VIPStudy1 (Fri @ 15.44 CET, 14.44 GMT) and myself talking all things fistula! (Fri @ 14.30 CET, 13.30 GMT)